Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

詳細情報 詳細情報について

• CRID

  1360862408323697920

• DOI

  10.1016/s2665-9913(23)00157-1

• ISSN

  26659913

• Web Site

  https://api.elsevier.com/content/article/PII:S2665991323001571?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S2665991323001571?httpAccept=text/plain

• データソース種別

  • Crossref